Cargando…
A multiplex platform for the identification of ovarian cancer biomarkers
BACKGROUND: Currently, there are no FDA approved screening tools for detecting early stage ovarian cancer in the general population. Development of a biomarker-based assay for early detection would significantly improve the survival of ovarian cancer patients. METHODS: We used a multiplex approach t...
Autores principales: | Boylan, Kristin L. M., Geschwind, Kate, Koopmeiners, Joseph S., Geller, Melissa A., Starr, Timothy K., Skubitz, Amy P. N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634875/ https://www.ncbi.nlm.nih.gov/pubmed/29051715 http://dx.doi.org/10.1186/s12014-017-9169-6 |
Ejemplares similares
-
Gene expression identifies heterogeneity of metastatic behavior among gastrointestinal stromal tumors
por: Skubitz, Keith M., et al.
Publicado: (2016) -
Quantitative proteomic analysis by iTRAQ(® )for the identification of candidate biomarkers in ovarian cancer serum
por: Boylan, Kristin LM, et al.
Publicado: (2010) -
Mathematical Prognostic Biomarker Models for Treatment Response and Survival in Epithelial Ovarian Cancer
por: Nikas, Jason B., et al.
Publicado: (2011) -
Evaluation of the potential of Pap test fluid and cervical swabs to serve as clinical diagnostic biospecimens for the detection of ovarian cancer by mass spectrometry-based proteomics
por: Boylan, Kristin L. M., et al.
Publicado: (2021) -
Development of a Multiprotein Classifier for the Detection of Early Stage Ovarian Cancer
por: Boylan, Kristin L. M., et al.
Publicado: (2022)